News

Sale of Somatex

Westlake Partners is glad to announce the sale of its portfolio company SOMATEX Medical Technologies GmbH, a leader in biopsy site markers and localization technologies, to Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women’s health.

Westlake Partners acquired SOMATEX in 2014 and since then, has successfully internationalized, innovated, professionalized and grown the company by an active management approach. The acquisition of SOMATEX supports Hologic’s strategy to provide a comprehensive suite of innovative solutions across the continuum of breast health care. 

“During the investment period, we reached some key milestones with SOMATEX: We developed a clear strategic focus, optimized organizational structures and processes, we launched several innovative products and expanded the global footprint of SOMATEX with sales offices in the U.S. and China.” said André Cerbe, Investment Director of Westlake Partners and former Managing Director of SOMATEX. 

Westlake Partners is a circle of international entrepreneurs and investors with extensive experience building companies. Following an entrepreneurial and collaborative approach, Westlake seeks active investments into small and medium-sized companies by providing both growth capital as well as strategic and operational support transforming them into global leaders in their niche.